
Investigation of the antiviral activity of the recombinant human interferon lambda 1 in human conjunctiva cell culture
Author(s) -
N. A. Kikhtenko,
T. N. Ilyicheva,
А. Г. Дурыманов,
А. Ж. Фурсова,
П. Г. Мадонов
Publication year - 2021
Publication title -
sibirskij naučnyj medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2410-2520
pISSN - 2410-2512
DOI - 10.18699/ssmj20210504
Subject(s) - conjunctiva , virology , interferon , antiviral drug , immunology , recombinant dna , virus , medicine , in vitro , pharmacology , biology , biochemistry , gene
The aim of the study was to determine the efficacy of recombinant human interferon lambda 1 (IFN-λ1) against human adenovirus serotype 5 in a culture of human conjunctival cells Chang conjunctiva clone 1-5c-4. Material and methods. The study design consisted of three experimental schemes, reflecting a prophylactic and two options for a therapeutic and prophylactic treatment regimen (with the constant presence of the virus in the culture medium and with its removal after adsorption). The antiviral activity of IFN-λ1 was determined by the number of viable cells after exposure to the virus (MTT test). Results and discussion. It has been established that IFN-λ1 has antiviral activity against human adenovirus in vitro under a prophylactic and therapeutic-prophylactic scheme of administration at an infection dose of 1 and 10 TCID 50 (50% tissue culture infectious dose), but not at an infection dose of 100 TCID 50 . The antiviral effect of the use of IFN-λ1 in a therapeutic and prophylactic regimen at an infection dose of 1 TCID 50 was comparable to that of IFN-α. At the same time, both interferons did not have a toxic effect on the cell culture even at a concentration of 84 and 58 μg/ml, respectively. The antiviral activity and the absence of cytotoxic action provide the basis for further study of the possibility of development of based on IFN-λ1 drug for eye conjunctiva viral diseases treatment.